| Document |
Document Title |
|
WO/2002/053534A1 |
Compounds represented by the general formula (I) or salts thereof, and medicines containing the same: (I) [wherein W is W?A¿-A?1¿-W?B¿- (wherein W?A¿ is optionally substituted aryl or the like; A?1¿ is -NR?1¿-, a single bond, -C(O)...
|
|
WO/2002/053547A1 |
Alkanoic acid derivatives represented by the general formula (I) or salts thereof, useful as preventive and/or therapeutic agents for diabetes, hyperlipidemia, impaired glucose tolerance, and so on: (I) wherein R?1¿ is an optionally sub...
|
|
WO/2002/051821A1 |
Compounds of the formula (I) for use as an estrogen receptor -$g(b)-selective ligand are described wherein: X is O or S; and R?1¿, R?3¿ R?6¿ are as described in the specification. The use of these compounds in treating Alzheimer's dis...
|
|
WO/2002/051983A2 |
The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making
|
|
WO/2002/051820A1 |
Compounds represented by the following general formula (I): (I) wherein each symbol has the meaning as defined in the description; salts thereof and drugs for controlling peroxisome proliferation-activated receptor which contain these co...
|
|
WO/2002/049632A1 |
Medicines having inhibitory activity against the activation of NF-kB, which contain as the active ingredient compounds represented by the general formula (I)(wherein X is a connecting group; A is hydrogen or acetyl; E is aryl or heteroar...
|
|
WO/2002/050045A1 |
This invention relates to compounds of formula I their salts, and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions comprising these compounds and their use in the treatment of picornavirus infections in mammal...
|
|
WO/2002/050081A2 |
Compounds of formula (I) and (IA) have antibacterial or antiprotozoal activity: formula (1) formula (2) wherein: Z represents a radical of formula N(OH)CH(=O) or of formula C(=O)NH(OH); R¿1? represents hydrogen, methyl or trifluoromethy...
|
|
WO/2002/050046A1 |
Compound of formula (I), wherein X is C¿1-6? alkylene or C¿2-6? alkenylene, each of which is optionally substituted by one or more flluorine atoms; R is aryl or C¿3-8? cycloalkyl optionally substituted by one or more fluorine atoms; W...
|
|
WO/2002/048106A2 |
Isoindolin-1-one-substituted propionamide glucokinase activators which increase insulin secretion in the treatment of type II diabetes of formula (I) wherein A is unsubstituted phenyl or phenyl which is mono- or di-substituted with halo ...
|
|
WO/2002/048139A2 |
Disclosed are novel compounds that are useful and effective as photoaffinity probes and methods of using oxazolidinone photoaffinity probes.
|
|
WO/2002/048121A1 |
The invention relates to cyclohexenone derivatives of benzazolons of general formula (I), wherein the variables R?1¿, R?2¿, R?3¿, A and Hex have the meaning as cited in claim 1, and the salts thereof, and the use thereof for controlli...
|
|
WO/2002/048140A1 |
Pyrazolylbenzazolones of general formula (I), in which groups R?1¿, R?2¿, R?3¿, A and Pz have the meanings given in claim 1, the salts and use thereof for treating noxious plants are disclosed.
|
|
WO/2002/048118A1 |
Compounds having the formula: wherein R¿1? represents hydrogen, C¿1?-C¿20? alkyl which is unsubstituted or substituted by one or more ammonium, mono-, di-, tri or tetra-C¿1?-C¿12? alkylammonium groups or by one or more sulphonium gr...
|
|
WO/2002/046173A1 |
Glucokinase activating compounds or pharmaceutically acceptable salts of Formula I-0: wherein M is Formula II or Formula III; Q is Formula IV or Formula V; R?1¿ is an alkyl having from 1 to 3 carbon atoms; R?2¿ is hydrogen, halo, nitro...
|
|
WO/2002/046150A2 |
Compounds which mimic the chemical and/or biological activity of discodermolide are provided and intermediates useful in their preparation.
|
|
WO/2002/046129A2 |
Compounds having the formula or therapeutically acceptable salts thereof, are histone deacetylase (HDAC) inhibitors. Preparation of the compounds, compositions containing the compounds, and treatment of diseases using the compounds are d...
|
|
WO/2002/044156A2 |
Benzimidazole derivatives of Formula (I), which are useful as TIE-2 and/or VEGFR2 inhibitors are described herein. The described invention also includes methods of making such benzimidazole derivatives as well as methods of using the sam...
|
|
WO/2002/044144A2 |
Radiolabeled fluorinated compounds useful for imaging in the diagnosis of Parkinson's Disease are disclosed. Methods and kits for their synthesis are also disclosed.
|
|
WO/2002/043716A2 |
A method for delaying or preventing an increase in prostate gland volume in humans or non-human mammals, which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of an insulin sensitiser...
|
|
WO/2002/044139A1 |
The invention concerns compounds of formula (I), wherein: A is a group of formula (a) or (b), their salts or solvates, pharmaceutical compositions containing them, a method for preparing them and intermediates used in said method. The co...
|
|
WO/2002/044145A1 |
There is provided a compound of formula (I) wherein R?a¿, R?1¿, R?2¿, Y and R?3¿ have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are use...
|
|
WO/2002/042273A2 |
Compounds having the formula (I), are useful as serine protease inhibitors, more particularly inhibitors of Factors VIIa, Ixa, Xa, and/or Xia, wherein ring B is phenyl or pyridyl, W is preferably C(=O)NR¿4?R¿5?, L is a linker group, XÂ...
|
|
WO/2002/043449A1 |
A luminescent element which comprises an anode, a cathode, and a luminescent substance interposed therebetween and which luminesces upon reception of electric energy, characterized by having at least one of the following compounds (a) to...
|
|
WO2001042179A9 |
Compounds which mimic the chemical and/or biological activity of discodermolide are provided and intermediates useful in their preparation.
|
|
WO/2002/040444A1 |
Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any di...
|
|
WO/2002/040445A1 |
A novel class of compounds of the general formula (I): wherein B is (1), (2), (3) or (4), Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromaic ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen a...
|
|
WO/2002/038120A1 |
The present invention relates to photo-labile pro-fragrance conjugates comprising: a) a photo-labile unit which upon exposure to electromagnetic radiation is capable of releasing a pro-fragrance unit; and b )a pro-fragrance unit, which w...
|
|
WO/2002/038532A1 |
A natural type $g(a)-amino acid which is easily available and inexpensive is converted to a compound represented by the formula (1), which is reacted with an organometallic reagent represented by the formula (2) to obtain an optically ac...
|
|
WO/2002/036553A2 |
The invention is directed to physiologically active compounds of general formula (1): wherein:- A?1¿ represents (i) a saturated 3 to 6 membered carbocycle, optionally substituted by one or more alkyl groups, (ii) indanyl or (iii) a satu...
|
|
WO/2002/032886A1 |
The present invention provides a process for the preparation of a compound of formula (I) wherein Y represents -O-, -S- or -N(R¿2?)-, R¿2? being hydrogen, C¿1?-C¿10?alkyl or aralkyl; Z represents a 2,5-furanyl, 2,5-thiophenyl, 4,4'-s...
|
|
WO/2002/032869A2 |
Substituted heterocyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted h...
|
|
WO/2002/032874A2 |
Substituted heterocyclic compounds for treating multidrug resistance are disclosed. Compositions and methods of use for the substituted heterocyclic compounds are disclosed. Suitable substituted heterocyclic compounds include Formula (I).
|
|
WO/2002/032897A1 |
The instant invention provides beta¿3? adrenergic receptor agonists of structural Formula (I), wherein Ar is pyridyl, oxazolyl, thiazolyl or phenyl; Rs is a S- or 6- membered heterocycle; X is a direct bond or oxygen; and Y is a direct ...
|
|
WO/2002/032871A2 |
Substituted acyclic compounds are disclosed. The compounds are useful for treating multidrug resistance. The compounds can be formulated in compositions with a carrier and, optionally, a therapeutic agent. One suitable substituted acycli...
|
|
WO/2002/032844A2 |
The invention relates to racemic and especially non-racemic acyloins, the derivatives thereof, a method for the production thereof and the use of the same for producing epothilones and their derivatives. The invention especially relates ...
|
|
WO/2002/032857A1 |
Methods of synthesizing pharmacologically useful oxazolidinones are disclosed, and, in particular, a method of manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protect...
|
|
WO/2002/032868A2 |
Compounds, compositions, and methods for treating multidrug resistance are disclosed. Suitable compounds are 2-substituted heterocyclic compounds. An example compound has the formula (I).
|
|
WO/2002/030929A1 |
Pleuromutilin compounds of the formula (A) & (B) are of use in anti-bacterial therapy.
|
|
WO/2002/028821A2 |
The invention relates to the PPAR-alpha activating compounds of general formula (I), for treating for example coronary heart diseases, and to a method for producing said compounds, wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R?6¿, R?7¿,...
|
|
WO/2002/028844A1 |
Compounds of the general formula (I), their optical isomers or prodrugs, pharmaceutically acceptable salts of the compounds, the isomers, or the prodrugs, or solvates of the same; and metalloprotease inhibitors containing the compounds, ...
|
|
WO/2002/027093A1 |
The invention provides textile auxiliaries exhibiting an excellent softening effect particularly for cellulosic textile materials, and textile materials treated with these auxiliaries have advantages of being excellent in durability to w...
|
|
WO/2002/026695A2 |
Disclosed are processes for the preparation of enantiomerically-enriched cyclopropylalanine derivatives by the hydrogenation of certain enamides in the presence of a catalyst comprising a transition metal and a substantially enantiomeric...
|
|
WO/2002/026683A1 |
A novel tandem acyl-Claisen rearrangement reaction is provided. An allylic reactant such as an allylic amine or an allylic thioether, having at least two functional groups that enable the reactant to undergo at least two successive Clais...
|
|
WO/2002/024669A1 |
A process for preparing 5-hydroxymethyl-2-oxazolidinone (1), preferably optically active, in one step from 3,4-boronic acid ester protected 3,4-dihydroxybutyramides (2) is described. The oxazolidinone is important in the pharmaceutical i...
|
|
WO/2002/024200A1 |
The present invention relates to thiazoles, oxazoles, imidazoles and pharmaceutical compositions comprising said compounds antagonizing the corticotropin releasing factor receptor ('CRF receptor') and useful for the treatment of depressi...
|
|
WO/2002/024793A1 |
The present invention is directed toward the renewable surface treatment of medical devices such as contact lenses and medical implants. In particular, the present invention is directed to a method of modifying the surface of a medical d...
|
|
WO/2002/024635A2 |
The present invention relates to a compound formula (I) wherein X¿1? is bond or -O-CH¿2?-, (II) or (III) R?1¿ is hydrogen or an amino protective group, a is phenyl, indolyl or carbazolyl, each of which may be substituted with one or t...
|
|
WO/2002/024670A1 |
A method for preparing protected, preferably chiral, 5-trityloxymethyl-oxazolidinone in one step directly from optically active 3-hydroxy-4-trityloxybutyramide is described. Oxazolidinones are animportant class of molecules in the pharma...
|
|
WO/2002/024636A2 |
N-Benzoyl arylsulfonamides having the formula (I) are BCL-Xl inhibitors and are useful for promoting apoptosis. Also disclosed are BCL-Xl inhibiting compositions and methods of promoting apoptosis in a mammal.
|
